

REMARKS

Claims 1, 3-10, 12, 13, and 15-25 were pending prior to this reply. In the non-final Office Action dated May 11, 2010, the Examiner rejected claims 1, 3-8, 10, 12, and 16-25 under 35 USC §112. Claim 9 was objected, but indicated to be allowable if drafted in independent fashion. Claims 13 and 15 had been withdrawn from consideration.

In this Amendment, claims 1, 3-8, 10, 12, and 15-25 have been cancelled without prejudice.

Claim 9 has been amended and is independent. Claim 10 has been amended to depend on claim 9. New claims 26, 27, and 28 have been added.

The amendments made herein have been made to progress prosecution of the instant case. These amendments are made without prejudice to Applicants' right to pursue subject matter disclosed in the specification, whether or not it has been deleted in this or any other amendment of the instant application, in subsequent continuation or divisional applications.

Reconsideration of the application in light of these amendments is hereby requested.

CONCLUSION

It is believed that all the claims in the application are now in condition for allowance. Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned at the number below.

The Commissioner is hereby authorized in this, concurrent, and future amendments and replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR §1.16 or §1.17, and any necessary extension of time fees, to Deposit Account No. 07-1392.

Respectfully submitted,

/James P. Riek/

James P. Riek
Attorney for Applicants
Registration No. 39,009

Date: 9 November 2010
Customer No. 23347
GlaxoSmithKline
Global Patents
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8022
Facsimile: (919) 483-7977